OTCMKTS:ABLYF - Ablynx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ablynx NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $50.63 0.00 (0.00 %) (As of 04/30/2019) Add Compare Today's Range$50.63Now: $50.63▼$50.6350-Day Range$50.63MA: $50.63▼$50.6352-Week Range$12.50Now: $50.63▼$55.04VolumeN/AAverage VolumeN/AMarket Capitalization$3.81 billionP/E RatioN/ADividend YieldN/ABeta1.99 ProfileAdvanced ChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ABLYF Previous SymbolNASDAQ:ABLYF CUSIPN/A CIKN/A Webhttp://www.ablynx.com/ Phone329-262-0000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$62.73 million Price / Sales60.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book18.68Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares75,250,000Market Cap$3.81 billion Next Earnings DateN/A OptionableNot Optionable Receive ABLYF News and Ratings via Email Sign-up to receive the latest news and ratings for ABLYF and its competitors with MarketBeat's FREE daily newsletter. OTC:ABLYF Rates by TradingView Ablynx (OTCMKTS:ABLYF) Frequently Asked Questions What is Ablynx's stock symbol? Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF." Has Ablynx been receiving favorable news coverage? News headlines about ABLYF stock have been trending positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ablynx earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Ablynx. Who are some of Ablynx's key competitors? Some companies that are related to Ablynx include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA). What other stocks do shareholders of Ablynx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ablynx investors own include China New Energy (CNEL), Bank of Ireland (IREBY), Pluristem Therapeutics (PSTI), ABLYNX NV/ADR (ABLX), GALAPAGOS NV/S (GLPG), Editas Medicine (EDIT), Check Point Software Technologies (CHKP), China Biologic Products (CBPO), Atlantica Yield (AY) and argenx (ARGX). Who are Ablynx's key executives? Ablynx's management team includes the folowing people: Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)Mr. Wim Ottevaere, Chief Financial Officer (Age 62)Mr. Piet Houwen, Chief Operations OfficerDr. Robert Friesen Ph.D., Chief Scientific OfficerLies Vanneste, Director of Investor Relations How do I buy shares of Ablynx? Shares of ABLYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Ablynx's stock price today? One share of ABLYF stock can currently be purchased for approximately $50.63. How big of a company is Ablynx? Ablynx has a market capitalization of $3.81 billion and generates $62.73 million in revenue each year. View Additional Information About Ablynx. What is Ablynx's official website? The official website for Ablynx is http://www.ablynx.com/. How can I contact Ablynx? Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The company can be reached via phone at 329-262-0000. MarketBeat Community Rating for Ablynx (OTCMKTS ABLYF)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 259 (Vote Outperform)Underperform Votes: 327 (Vote Underperform)Total Votes: 586MarketBeat's community ratings are surveys of what our community members think about Ablynx and other stocks. Vote "Outperform" if you believe ABLYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABLYF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: Closed-End Mutual Funds
